Myopathy in older people receiving statin therapy: A systematic review and meta-analysis

British Journal of Clinical Pharmacology

Volumn 80, Issue 3, 2015, Pages 363-371

  Iwere, Roli B ^a   Hewitt, Jonathan ^a  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

adverse effects; aged; elderly; myalgia; myopathy; statin

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

AGED; ARTICLE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOLLOW UP; GERIATRIC PATIENT; HUMAN; INFORMATION RETRIEVAL; META ANALYSIS; MONOTHERAPY; MYOPATHY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHABDOMYOLYSIS; RISK ASSESSMENT; RISK FACTOR; SECONDARY PREVENTION; SYSTEMATIC REVIEW; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; AGE; CHEMICALLY INDUCED; CLINICAL TRIAL (TOPIC); FACTUAL DATABASE; MUSCULAR DISEASES; RISK; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; CLINICAL TRIALS AS TOPIC; DATABASES, FACTUAL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MUSCULAR DISEASES; RISK;

EID: 84940453791     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12687     Document Type: Article

References (53)

1. Sathasivam S,. Statin induced myotoxicity. Eur J Intern Med 2012; 23: 317-24.
2. Rosenson RS, Baker SK, Jacobson TA, Kopecky SL, Parker BA,. An assessment by the Statin Muscle Safety Task Force: 2014 update. J Clin Lipidol 2014; 8 (3 Suppl.): S58-71.
3. Jukema JW, Cannon CP, de Craen AJM, Westendorp RGJ, Trompet S,. The controversies of statin therapy: weighing the evidence. J Am Coll Cardiol 2012; 60: 875-81.
4. Cohen JD, Brinton EA, Ito MK, Jacobson TA,. Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10 138 current and former statin users. J Clin Lipidol 2012; 6: 208-15.
5. Mohassel P, Mammen AL,. The spectrum of statin myopathy. Curr Opin Rheumatol 2013; 25: 747-52.
6. Bhardwaj S, Selvarajah S, Schneider EB,. Muscular effects of statins in the elderly female: A review. Clin Interv Aging 2013; 8: 47-59.
7. El Desoky ES,. Pharmacokinetic-pharmacodynamic crisis in the elderly. Am J Ther 2007; 14: 488-98.
8. Parker BA, Thompson PD,. Effect of statins on skeletal muscle: exercise, myopathy, and muscle outcomes. Exerc Sport Sci Rev 2012; 40: 188-94.
9. Allen Maycock CA, Muhlestein JB, Horne BD, Carlquist JF, Bair TL, Pearson RR,. Statin therapy is associated with reduced mortality across all age groups of individuals with significant coronary disease, including very elderly patients. J Am Coll Cardiol 2002; 40: 1777-85.
10. Farmer JA, Gotto AM,. The Heart Protection Study: expanding the boundaries for high-risk coronary disease prevention. Am J Cardiol 2003; 92: 3-9.
11. Deedwania P, Stone PH, Bairey Merz CN, Cosin-Aguilar J, Koylan N, Luo D,. Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE). Circulation 2007; 115: 700-7.
12. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM,. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet 2002; 360: 1623-30.
13. Szadkowska I, Stanczyk A, Aronow WS, Kowalski J, Pawlicki L, Ahmed A,. Statin therapy in the elderly: A review. Arch Gerontol Geriatr 2010; 50: 114-8.
14. Foley KA, Simpson RJ, Crouse JR, Weiss TW, Markson LE, Alexander CM,. Effectiveness of statin titration on low-density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events. Am J Cardiol 2003; 92: 79-81.
15. Jacobson TA,. Overcoming "ageism" bias in the treatment of hypercholesterolaemia : A review of safety issues with statins in the elderly. Drug Saf 2006; 29: 421-48.
16. Alexander KP, Blazing MA, Rosenson RS, Hazard E, Aronow WS, Smith SC,. Management of hyperlipidemia in older adults. J Cardiovasc Pharmacol Ther 2009; 14: 49-58.
17. Jamal SM, Eisenberg MJ, Christopoulos S,. Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am Heart J 2004; 147: 956-65.
18. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr,. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA 1998; 279: 1615.
19. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ,. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-96.
20. Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R,. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): A randomised, double-blind, placebo-controlled trial. Lancet 2008; 372: 1231-9.
21. Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM, Kastelein JJP,. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195-207.
22. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters DD,. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL Study: A randomized controlled trial. JAMA 2001; 285: 1711.
23. Pedersen TR,. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
24. Pitt B, Mancini GBJ, Ellis SG, Rosman HS, Park JS, McGovern ME,. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. J Am Coll Cardiol 1995; 26: 1133-9.
25. Law M, Rudnicka AR,. Statin safety: A systematic review. Am J Cardiol 2006; 97: 52C-60.
26. Rosenson RS,. Current overview of statin-induced myopathy. Am J Med 2004; 116: 408-16.
27. Higgins JPT,. The Cochrane Collaboration tool for assessing risk of bias (Table 8.5.a) [online]. 2011. Available at http://handbook.cochrane.org/chapter-8/table-8-5-a-the-cochrane-collaborations-tool-for-assessing.htm (last accessed 25 February 2014).
28. Egger M, Smith GD, Phillips AN,. Meta-analysis: principles and procedures. BMJ 1997; 315: 1533-7.
29. Higgins JPT, Green S,. Recommendations on testing for funnel plot asymmetry. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0, 2011 [online]. Available at http://handbook.cochrane.org/chapter-10/10-4-3-1-recommendations-on-testing-for-funnel-plot-asymmetry.htm (last accessed 25 August 2014).
30. Holdaas H, Fellström B, Jardine AG, Holme I, Nyberg G, Fauchald P,. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: A multicentre, randomised, placebo-controlled trial. Lancet 2003; 361: 2024-31.
31. Sacks FM, Pfeffer MA, Moyé L, Rouleau JL, Rutherford JD, Cole TG,. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-9.
32. Kjekshus J, Apetrei E, Barrios V, Bohm M, Cleland JGF, Cornel JH,. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007; 357: 2249-61.
33. Bradford RH, Shear CL, Chremos AN, Dujovne C, Downtown M, Franklin FA,. Expanded clinical evaluation of lovastatin (EXCEL) study results I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolaemia. Arch Intern Med 1991; 151: 43-9.
34. Giannini SD, De Goes JM, Dereviacki BE, Machado C, Forti N, Diament J,. Simvastatin in the treatment of elderly patients with primary hypercholesterolemia. Curr Ther Res 1994; 55: 161-71.
35. Anon. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-57.
36. Serruys PWJC,. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: A randomized controlled trial. JAMA 2002; 287: 3215.
37. Anon. Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. The Pravastatin Multinational Study Group for Cardiac Risk Patients. Am J Cardiol 1993; 72: 1031-7.
38. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R,. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-504.
39. Armitage J, Bowman L, Wallendszus K, Bulbulia R, Rahimi K, Haynes R,. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: A double-blind randomised trial. Lancet 2010; 376: 1658-69.
40. Stolcpart RS, Olson KL, Delate T, Rasmussen J, Rehring TF, Merenich JA,. The risk for significant creatine kinase elevation with statins. Am J Cardiovasc Drugs 2010; 10: 187-92.
41. LaRosa JC, Grundy SM, Waters DD, Shear CL, Barter P, Fruchart JC,. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425-35.
42. Bigger JT,. Issues in subgroup analyses and meta-analyses of clinical trials. J Cardiovasc Electrophysiol 2003; 14: S6-8.
43. Naggara O, Raymond J, Guilbert F, Altman DG,. The problem of subgroup analyses: an example from a trial on ruptured intracranial aneurysms. Am J Neuroradiol 2011; 32: 633-6.
44. Collins R, Armitage J, Parish S, Sleight P, Peto R,. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
45. Fernandez G, Spatz ES, Jablecki C, Phillips PS,. Statin myopathy: A common dilemma not reflected in clinical trials. Cleve Clin J Med 2011; 78: 393-403.
46. Joy TR, Hegele RA,. Narrative review: statin-related myopathy. Ann Intern Med 2009; 150: 858.
47. Macedo AF, Taylor FC, Casas JP, Adler A, Prieto-Merino D, Ebrahim S,. Unintended effects of statins from observational studies in the general population: systematic review and meta-analysis. BMC Med 2014; 12: 51.
48. Roberts CGP, Guallar E, Rodriguez A,. Efficacy and safety of statin monotherapy in older adults: A meta-analysis. J Gerontol Ser A Biol Sci Med Sci 2007; 62: 879-87.
49. Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B,. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study. Cardiovasc Drugs Ther 2005; 19: 403-14.
50. Stewart A,. SLCO1B1 polymorphisms and statin-induced myopathy. PLoS Curr 2013; 5: pii.
51. Silva MA, Swanson AC, Gandhi PJ, Tataronis GR,. Statin-related adverse events: A meta-analysis. Clin Ther 2006; 28: 26-35.
52. Bitzur R, Cohen H, Kamari Y, Harats D,. Intolerance to statins: mechanisms and management. Diabetes Care 2013; 36 (Suppl. 2): S325-30.
53. Di Stasi SL, MacLeod TD, Winters JD, Binder-Macleod SA,. Effects of statins on skeletal muscle: A perspective for physical therapists. Phys Ther 2010; 90: 1530-42.